News
Jazz Pharma’s blood cancer therapy Rylaze wins US approval
The US Food and Drug Administration has approved Dublin-based Jazz Pharmaceutical’s Rylaze for the treatment of two blood cancers – acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL).